CT based three dimensional dose-volume evaluations for high-dose rate intracavitary brachytherapy for cervical cancer

Murakami, Naoya; Kasamatsu, Takahiro; Wakita, Akihisa; Nakamura, Satoshi; Okamoto, Hiroyoki; Inaba, Koji; Morota, Madoka; Ito, Yoshiaki; Sumi, Minako; Itami, Jun

doi:10.1186/1471-2407-14-447

Cited by 61 publications

(78 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This difference was caused by the CS technique. According to other reports from Japan, although treatment outcomes were excellent, HR-CTV D90s were less than 70 Gy [18,19]. These results are also lower than our findings.…”

Section: Reported Treatment Resultscontrasting

confidence: 57%

“…In addition, we continue to use a CS technique with EBRT and pelvic IMRT has not been accepted in the definitive RT for cervical cancer. Therefore, although successful outcomes were reported [18,19], RT for cervical cancer in Japan is still different from that in European countries in both BT and EBRT. In the immediate future, a new treatment protocol (MRI-or CT-based?…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Image‐Guided Adaptive Brachytherapy for Cervical Cancer Using Magnetic Resonance Imaging: Overview and Experience

Yoshida¹,

Nishikawa²,

Miyawaki³

et al. 2017

Radiotherapy

View full text Add to dashboard Cite

Image-guided adaptive brachytherapy (IGABT) using magnetic resonance imaging (MRI) has been accepted as a novel treatment technique for cervical cancer. During the development of MRI-based IGABT, a very important concept called "High-risk clinical target volume (HR-CTV)" was introduced. However, computed tomography (CT)-based IGABT is the most common modality in Japan.MRI-based IGABT was initiated in September 2014 at Kobe University Hospital and 50 patients were treated through March 2016. Although a total HR-CTV D90 ranging from 80 to 85 Gy equivalent dose in 2 Gy fractions in combination with 45 Gy of external beam radiotherapy (EBRT) and 7 Gy×4 fractions of IGABT is the most standard treatment aim in European institutions, our aim for a total HR-CTV D90 was a 70-80 Gy because of the use of the central shielding technique for the protection of organs at risk in the late phase of EBRT.The mean total HR-CTV D90 for our 50 patients was 77 Gy. Although our aim was achieved, it was relatively low because Japanese radiotherapy protocols for cervical cancer still differ from those in European institutions. Therefore, a new treatment protocol, which is closer to the global standard, should be established.

show abstract

Section: Reported Treatment Resultscontrasting

confidence: 57%

Section: Discussionmentioning

confidence: 99%

Image‐Guided Adaptive Brachytherapy for Cervical Cancer Using Magnetic Resonance Imaging: Overview and Experience

Yoshida¹,

Nishikawa²,

Miyawaki³

et al. 2017

Radiotherapy

View full text Add to dashboard Cite

show abstract

“…In ovarian cancer, RhoC overexpression promotes EMT, invasion, and metastasis, and RhoC knockout reverses the promoter role of vascular endothelial growth factor (VEGF) and transforming growth factor (TGF) in EMT [16]. In a previous study, we found that miR-93 downregulates RhoC to inhibit migration and invasion in ovarian cancer [17].…”

Section: Discussionmentioning

confidence: 99%

“…In ovarian cancer, Ras homolog family member C (RhoC) overexpression promotes EMT and increased migration and invasion ability [16]. In our previous study, we found that miR-93 downregulated RhoC to inhibit cell migration and invasion in ovarian cancer [17].…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-93 Promotes Epithelial–Mesenchymal Transition of Endometrial Carcinoma Cells

Chen

Sun

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

MicroRNA-93, derived from a paralog (miR-106b-25) of the miR-17-92 cluster, is involved in the tumorigenesis and progression of many cancers such as breast, colorectal, hepatocellular, lung, ovarian, and pancreatic cancer. However, the role of miR-93 in endometrial carcinoma and the potential molecular mechanisms involved remain unknown. Our results showed that miR-93 was overexpressed in endometrial carcinoma tissues than normal endometrial tissues. The endometrial carcinoma cell lines HEC-1B and Ishikawa were transfected with miR-93-5P, after which cell migration and invasion ability and the expression of relevant molecules were detected. MiR-93 overexpression promoted cell migration and invasion, and downregulated E-cadherin expression while increasing N-cadherin expression. Dual-luciferase reporter assay showed that miR-93 may directly bind to the 3′ untranslated region of forkhead box A1 (FOXA1); furthermore, miR-93 overexpression downregulated FOXA1 expression while miR-93 inhibitor transfection upregulated FOXA1 expression at both mRNA and protein level. In addition, transfection with the most effective FOXA1 small interfering RNA promoted both endometrial cancer cell migration and invasion, and downregulated E-cadherin expression while upregulating N-cadherin expression. Therefore, we suggest that miR-93 may promote the process of epithelial–mesenchymal transition in endometrial carcinoma cells by targeting FOXA1.

show abstract

“…All brachytherapy was carried out by 192 Ir remote after loading system (RALS, Microselectron HDR ™ , Nucletron, Veennendaal, The Netherlands). From 2008, computed tomography (CT)-based image-guided ICBT for uterine cervical cancer patients was started in our department [16], and CT-based image-guided HDR-ISBT was started in the same year. Hybrid brachytherapy has started from 2010 for tumors with mild to moderate parametrial invasion that could not be adequately covered with ICBT [16, 17].…”

Section: Methodsmentioning

confidence: 99%

The role of interstitial brachytherapy in the management of primary radiation therapy for uterine cervical cancer

Murakami¹,

Kobayashi²,

Kato

et al. 2016

jcb

Self Cite

View full text Add to dashboard Cite

PurposeThe aim of this study was to report the clinical results of uterine cervical cancer patients treated by primary radiation therapy including brachytherapy, and investigate the role of interstitial brachytherapy (ISBT).Material and methodsAll consecutive uterine cervical cancer patients who were treated by primary radiation therapy were reviewed, and those who were treated by ISBT were further investigated for clinical outcomes and related toxicities.ResultsFrom December 2008 to October 2014, 209 consecutive uterine cervical cancer patients were treated with primary radiation therapy. Among them, 142 and 42 patients were treated by intracavitary and hybrid brachytherapy, respectively. Twenty-five patients (12%) were treated by high-dose-rate (HDR)-ISBT. Five patients with distant metastasis other than para-aortic lymph node were excluded, and 20 patients consisted of the analysis. Three-year overall survival (OS), progression-free survival (PFS), and local control (LC) rate were 44.4%, 38.9%, and 87.8%, respectively. Distant metastasis was the most frequent site of first relapse after HDR-ISBT. One and four patients experienced grade 3 and 2 rectal bleeding, one grade 2 cystitis, and two grade 2 vaginal ulcer.ConclusionsFeasibility and favorable local control of interstitial brachytherapy for locally advanced cervical cancer was demonstrated through a single institutional experience with a small number of patients.

show abstract

CT based three dimensional dose-volume evaluations for high-dose rate intracavitary brachytherapy for cervical cancer

Cited by 61 publications

References 32 publications

Image‐Guided Adaptive Brachytherapy for Cervical Cancer Using Magnetic Resonance Imaging: Overview and Experience

Image‐Guided Adaptive Brachytherapy for Cervical Cancer Using Magnetic Resonance Imaging: Overview and Experience

MicroRNA-93 Promotes Epithelial–Mesenchymal Transition of Endometrial Carcinoma Cells

The role of interstitial brachytherapy in the management of primary radiation therapy for uterine cervical cancer

Contact Info

Product

Resources

About